Eli Lilly SG&A Expenses 2010-2024 | LLY

Eli Lilly sg&a expenses for the twelve months ending June 30, 2024 were $7.798B, a 12.49% increase year-over-year.

  • Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.
  • Eli Lilly annual sg&a expenses for 2022 were $6.44B, a 0.14% increase from 2021.
  • Eli Lilly annual sg&a expenses for 2021 were $6.432B, a 5.07% increase from 2020.

Eli Lilly SG&A Expenses 2010-2024 | LLY

  • Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.
  • Eli Lilly annual sg&a expenses for 2022 were $6.44B, a 0.14% increase from 2021.
  • Eli Lilly annual sg&a expenses for 2021 were $6.432B, a 5.07% increase from 2020.
Related Stocks
Company NameMarket
Cap
Novo Nordisk (NVO)$592.4B
Johnson & Johnson (JNJ)$402.2B
AbbVie (ABBV)$341.7B
Merck (MRK)$299.6B
AstraZeneca (AZN)$243.5B
Novartis AG (NVS)$236.5B
Pfizer (PFE)$169B
Sanofi (SNY)$144.1B
Innoviva (INVA)$1.2B